On the possibilities of combining budget impact analysis and cost-effectiveness analysis - development of «3D» pharmacoeconomic model

Yagudina, R.; Serpik, V.G.

doi:10.30809/phe.3.2014.8

Cited by 18 publications

(20 citation statements)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This pharmacoeconomic study had a retrospective design and was carried out using the following methods of pharmacoeconomic analysis: effectiveness analysis, cost analysis, cost-minimization analysis (CMA), cost-utility analysis (CUA), budget impact analysis (BIA) and modeling [9,[11][12][13][14][15]. A decision tree type of modeling was used in this pharmacoeconomic analysis.…”

Section: Methodsmentioning

confidence: 99%

Pharmacoeconomic analysis of medicines used in the treatment of pulmonary hypertension in the Russian Federation

Serpik¹,

Arinina²

2016

Pharmacoeconom T&P

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Pharmacoeconomic analysis of medicines used in the treatment of pulmonary hypertension in the Russian Federation

Serpik¹,

Arinina²

2016

Pharmacoeconom T&P

Self Cite

View full text Add to dashboard Cite

“…The cost-effectiveness ratio is 869,705 rubles for the treatment with lapatinib + capecitabine, and 3,461,960 rubles for the therapy with trastuzumab emtansine. This means that the use of lapatinib in combination with capecitabine is the cost-effective treatment from the point of view of pharmacoeconomics [25].…”

Section: Cost-effectiveness Analysismentioning

confidence: 99%

“…Despite the QALY value for lapatinib in combination with capecitabine, a lower CUR value suggests that the use of lapatinib in combination with capecitabine is the cost-effective treatment for HER-positive mBC from the pharmacoeconomic point of view. [22] Budget impact analysis This analysis allows prediction of the impact on the health budget and calculation of the economic effect that can be expressed as cost savings or increased costs after transition from the comparison therapy to the alternative therapy [25,27].…”

Section: Cost-utility Analysismentioning

confidence: 99%

Pharmacoeconomic analysis of lapatinib treatment in metastatic breast cancer with HER2+ overexpression

Kulikov¹,

Petrovskiy²,

Rybchenko³

et al. 2016

Pharmacoeconom T&P

View full text Add to dashboard Cite

show abstract

“…The result of this calculation has the same monetary value both for the patients who administered Kuvan combined with the dietary therapy and patients who used the dietary therapy alone and is 70,713 RUB for one patient per the treatment course. The equal value of these costs for both groups of patients is explained by the use of the standard of medical care for PKU patients, in which the medical services received by any patient with this diagnosis are listed [11,12]. …”

Section: Cost Analysismentioning

confidence: 99%

Pharmacoeconomic analysis of the use of the kuvan drug product in phenylketonuric patients

Kulikov¹,

Rybchenko²

2015

Pharmacoeconom T&P

View full text Add to dashboard Cite

A pharmacoeconomic study of the treatment of phenylketonuria (PHU) treatment using Kuvan drug product combined with the diet or dietary therapy alone has been conducted. It has been established that the therapy is dominant in the first case when compared to the second case because it shows better therapeutic effectiveness and is characterized by a lower costeffectiveness ratio. It has also been determined that the addition of Kuvan to the dietary therapy requires additional costs of 11,569,761 RUB per one patient over 16 years. Despite the increase in the costs linked to the use of the new and only drug for the treatment of PKU, the overall effect on the budget will be decreased due to the low prevalence of the disease. Keywords: pharmacoeconomic analysis, effectiveness, costs, costeffectiveness analysis, budget impact analysis, phenylketonuria, phenylalanine, Kuvan, sapropterin, dietary therapy.Introduction Phenylketonuria (PKU) is a challenging issue for the public healthcare system in the Russian Federation (RF) and other countries worldwide.PKU is a genetic disease that is inherited in an autosomal recessive fashion and results in the disturbance of the amino acid metabolism. Here, up to 1% of the cases of PKU is represented by the atypical forms associated with the mutations in other genes responsible for the coding for enzymes providing the synthesis of the cofactor of phenylalanine hydroxylase tetrahydrobioptherin (BH4). The clinical presentation of the disease develops in 2-3 weeks after the birth already and the irreversible changes in the central nervous system (CNS) develop in the child by the age of six month. Progressive intellectual disability, epilepsy syndrome, and other psychoneurological disorders are characteristic for the PKU patients [14].The occurrence of the methods for the drug treatment of PKU is of particular interest because dietary therapy is currently the main method of medical treatment. In 2007, the Food and Drug Administration of the USA (FDA) approved the Kuvan® (sapropterin) drug product (DP) that is the first medication capable of providing the body with BH4 in the PKU patients, thus making it possible to reduce the incapacitation and mortality and improve the patients' quality of life.This DP was registered within the territory of the RF on July 15, 2014 [9]. The introduction of Kuvan into practice will lead to the growth in the costs and burden on the budget of the public healthcare system. Therefore, the need for carrying out the pharmacoeconomic analysis of the use of the dietary therapy alone in comparison with the use of Kuvan combined with the dietary therapy in PKU patients emerges. Research procedureThe pharmacoeconomic assessment of the treatment of PKU patients with the Kuvan innovative drug product combined with the dietary therapy in comparison with the dietary therapy alone was performed as part of this study. These treatment regimens were used in children from 4 years to their adulthood with the initial weight of 14 kg. It was taken into account in the ...

show abstract

On the possibilities of combining budget impact analysis and cost-effectiveness analysis - development of «3D» pharmacoeconomic model

Cited by 18 publications

References 1 publication

Pharmacoeconomic analysis of medicines used in the treatment of pulmonary hypertension in the Russian Federation

Pharmacoeconomic analysis of medicines used in the treatment of pulmonary hypertension in the Russian Federation

Pharmacoeconomic analysis of lapatinib treatment in metastatic breast cancer with HER2+ overexpression

Pharmacoeconomic analysis of the use of the kuvan drug product in phenylketonuric patients

Contact Info

Product

Resources

About